Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDHemab Therapeutics Holdings Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$23.25 | -$23.25 | -$23.25 |
| Q2 2026 | 2 | -$0.80 | -$0.65 | -$0.73 |
| Q3 2026 | 2 | -$0.54 | -$0.44 | -$0.49 |
| Q4 2026 | 1 | -$0.59 | -$0.59 | -$0.59 |
| Q1 2027 | 1 | -$0.54 | -$0.54 | -$0.54 |
| Q2 2027 | 1 | -$0.64 | -$0.64 | -$0.64 |
| Q3 2027 | 1 | -$0.59 | -$0.59 | -$0.59 |
| Q4 2027 | 1 | -$0.71 | -$0.71 | -$0.71 |
Hemab Therapeutics Holdings Inc. Earnings Date And Information
Hemab Therapeutics Holdings Inc. last posted its earnings results on Thursday, May 21st, 2026. The company reported $-23.98 earnings per share for the quarter, missing analysts' consensus estimates of $-23.245 by $0.735. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Hemab Therapeutics Holdings Inc. has generated $-2 earnings per share over the last year ($-2.33 diluted earnings per share) and currently has a price-to-earnings ratio of -21.66. Hemab Therapeutics Holdings Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Hemab Therapeutics Holdings Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/31/2026 | Q1 2026 | N/A | -$0.51 | N/A | $0 | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Hemab Therapeutics Holdings Inc. Earnings: FAQ's
The conference call for Hemab Therapeutics Holdings Inc.'s latest earnings report can be listened to online.
The conference call transcript for Hemab Therapeutics Holdings Inc.'s latest earnings report can be read online.
Hemab Therapeutics Holdings Inc. (:COAG) has a recorded net income of $-63,913,000.Hemab Therapeutics Holdings Inc. has generated $-2.33 earnings per share over the last four quarters.
Hemab Therapeutics Holdings Inc. (:COAG) has a price-to-earnings ratio of -21.66 and price/earnings-to-growth ratio is -0.22.